BITFURY-GROUP
4.11.2021 13:02:08 CET | Business Wire | Press release
Bitfury Group (“Bitfury” or the “Company”), the Bitcoin mining and crypto tech pioneer, today announced that Brian P. Brooks, former United States Acting Comptroller of the Currency, has joined the Company as Chief Executive Officer, effective October 29, 2021. Mr. Brooks will lead the 10-year-old crypto unicorn as it launches a new funding round, increases the growth of its mining business with a revolutionary new microchip design and new global data center locations, and scales a portfolio of innovative businesses that grew out of the Company’s heritage as an early Bitcoin leader. Valery Vavilov, Founder of Bitfury, will become Chairman of the Board of Directors and Chief Vision Officer, where he will continue his focus on developing over-the-horizon hardware and software innovations for Bitfury as it builds the infrastructure for a tokenized global economy.
Mr. Vavilov said, “Since our founding, Bitfury has pioneered innovative blockchain hardware and software infrastructure, and today represents a comprehensive platform addressing and enhancing the full digital asset value chain. With an eye toward the next phase in our evolution, we are thrilled to welcome Brian to the Company. Brian is a respected executive and thought leader with deep regulatory, digital asset and capital markets expertise who shares Bitfury’s vision for a decentralized peer-to peer economy. Together, we will continue to execute Bitfury’s growth strategy and help businesses, governments, organizations, and individuals leverage the blockchain to solve the most pressing challenges of today and tomorrow.”
Since its inception in 2011, Bitfury has developed into a full-service blockchain technology company and one of the world’s leading providers of large-scale digital asset infrastructure solutions. Bitfury’s platform of emerging technologies businesses includes its self-mining operations, with seven ultra-low-cost energy sites globally alongside its new United-States based Cipher Mining subsidiary; hardware products for high-performance computing needs, including seven generations of its own specialized micro-chips and next generation immersion cooling systems; and software and enterprise blockchain solutions spanning security, payments, and applications for the creator economy, among others.
Mr. Brooks said, “Bitfury is an established leader in the digital asset industry, renowned for its sustained research and development efforts and best-in-class proprietary technologies. As the adoption of – and use cases for – Bitcoin, other cryptoassets, and their underlying blockchains continues to accelerate worldwide, the Company’s diversified portfolio has immense opportunity and is well positioned for long-term success. I look forward to working alongside Valery and Bitfury’s highly experienced leadership team to grow the Company’s core businesses and scale its portfolio of new innovations.”
Brian P. Brooks Biography
Most recently, Mr. Brooks served as Chief Executive Officer of digital asset exchange and marketplace Binance.US. Previously, from May 2020 to January 2021, Mr. Brooks served as the Acting Comptroller of the Currency, where he was the administrator of the federal banking system and the chief executive of the 3,500-employee federal agency responsible for chartering and supervising banks comprising 70 percent of all banking activity in the United States. He also served as a member of the board of directors of the Federal Deposit Insurance Corporation and a voting member of the Financial Stability Oversight Council. Often referred to in the media as “the first fintech Comptroller” and “CryptoComptroller” for his work advancing financial innovation, Mr. Brooks led the government’s efforts to provide regulatory clarity for stablecoins, digital asset custody, and the development of blockchain payment networks, and granted the first federal bank charter to a cryptocurrency company. He also launched Project REACh, a national partnership of civil rights organizations, tech companies, and banks to promote financial inclusion through greater access to credit and capital.
From 2018 to 2020, Mr. Brooks served as Chief Legal Officer of Coinbase Global, Inc., where he led legal, compliance, internal audit, government relations, and global investigations groups at the digital asset platform. From 2014 to 2018, he served as Executive Vice President, General Counsel, and Corporate Secretary of Fannie Mae, a $3.2 trillion asset public company that is the world’s largest investor in single-family and multifamily mortgage assets, and from 2011 to 2014, as Vice Chairman of OneWest Bank, N.A. Before joining OneWest Bank, N.A., he served as managing partner of O’Melveny & Myers LLP’s Washington, D.C. office.
Mr. Brooks also serves as an adviser or board member for a number of financial and fintech companies. Mr. Brooks received his BA from Harvard University and his JD from the University of Chicago.
About Bitfury Group
Bitfury Group is the world's leading technology company unlocking the full value chain of Bitcoin and other digital assets. Bitfury™ has built on its heritage as one of the earliest Bitcoin miners and developers of mining equipment to create solutions for the future – solutions such as the Crystal™ Blockchain advanced analytics platform, which helps law enforcement and private sector clients make cryptoassets safer and more compliant; the Liquidstack immersion cooling business, which dramatically reduces data center energy usage and makes Bitcoin mining and high performance computing more environmentally sustainable; Axelera AI, which unlocks the potential of artificial intelligence with the world’s most advanced AI technologies; Surround, providing blockchain-based solutions for the creator economy including digital rights management, payments, and NFT support; and others. Our mission is to make the world more secure and trusted by innovating at every level of technology – hardware, security, and software – to put trust back into the equation. To learn more, visit www.bitfury.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom